Kantify develops smart solutions for lifesciences, healthcare and biotechnology.
Zeptomics: drug discovery powered by Artificial Intelligence
AI powered In silico drug discovery for small molecules and Targeted Protein Degraders
Zeptotarget : in silico target identification
Discover our next generation AI solution to identify novel drug targets based on the output of phenotypic screens
Zeptohit : in silico hit discovery
Discover our next generation AI solution for discovery of hits and bioactivity
Zeptoward : in silico ADMET property prediction
Discover our next generation AI solution for discovery of absorption, distribution, metabolism, excretion, and toxicity properties
Zeptocure : in silico indication discovery
Discover our next generation AI solution for discovery of indications for repositioned or repurposed drugs
Predictive Diagnosis and CDC
AI solutions for diagnosis and clinical decision support. We help develop solutions in oncology, ophthalmology, hematology and others. Our expertise in AI for healthcare enables us to understand and tackle challenges in various therapeutical areas, using different datasets and sources.
Solutions to accelerate and improve the analysis of images, sequences, documents, samples and other kinds of clinical data. Our technologies enable laboratory operators and analysts to easily process large amounts of data, and immediately extract insights or detect patterns.
Artificial Intelligence in practice
Wed 11 May 2022
A new AI/ML approach for ligand identification
Only 1% of compound to protein interactions are currently known. We are on a mission to predict the remaining 99%.
Fri 29 Apr 2022
ADMET prediction with Artificial Intelligence : Publication
Peer reviewed publication "Dual Blockade of Misfolded Alpha-Sarcoglycan Degradation by Bortezomib and Givinostat Combination"
Mon 14 Mar 2022
Artificial Intelligence for Targeted Protein Degradation
Discover how Kantify’s AI -based drug discovery tool, Zeptomics, accelerates the discovery of promising Targeted Protein Degraders (PROTAC, DUBTAC, LYTAC,...),
Wed 26 Jan 2022
Machine learning for in-silico lead identification
Discover how AI can help you select promising lead compounds through predicting their ADMET properties and off-target side effects
Wed 22 Sep 2021
Detecting heart failure with AI: HeartKinetics and Kantify
Collaboration between Kantify and HeartKinetics around real-time detection and classification of heart failure
Thu 12 Aug 2021
AI for Breast Cancer Detection using whole-slide images
Step-by-step approach from data selection, cleaning and augmentation to training of a deep neural network for segmenting whole-slide images and counting nuclei.
Mon 30 May 2022
Targeted Protein Degradation : Kantify at Proteocure event
Kantify spoke about the latest progress of AI/ML for Degraders at the event of Proteocure
Mon 02 May 2022
Register to our webinar : Targeted Protein Degraders and AI
Discover how Artificial Intelligence can be used in the discovery and design of Targeted Protein Degraders.